StoneX Group’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

StoneX Group’s Portfolio LABU Stock Details LABU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-513	Closed	-$50.4K	–	421
2023 Q1	$50.4K	Buy	+513	New	+$69.6K	0.03%	326

Other funds holding LABU

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

IMC Chicago Chicago, Illinois $278B AUM 44.93% 1-Year Est. Return

Wolverine Trading Chicago, Illinois $139B AUM 31.83% 1-Year Est. Return

Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Gainplan Bloomfield Hills, Michigan $254M AUM 25.62% 1-Year Est. Return

StoneX Group's LABU Position: Q2 2023 in Review

StoneX Group sold out of Direxion Daily S&P Biotech Bull 3X ETF (LABU) in Q2 2023, closing a stake of 513 shares — an estimated $50.4K sold.

StoneX Group first reported a position in LABU in Q1 2023 and held it in 1 quarter. The position peaked at $50.4K in Q1 2023. 51 funds tracked by Wall St. Rank hold LABU as of Q2 2023.

StoneX Group reported no remaining Direxion Daily S&P Biotech Bull 3X ETF position as of Q2 2023 after selling out during the quarter.
StoneX Group sold 513 Direxion Daily S&P Biotech Bull 3X ETF shares in Q2 2023, an estimated $50.4K.
StoneX Group first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q1 2023 and held it in 1 quarter.
StoneX Group's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $50.4K in Q1 2023.
51 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q2 2023.

Based on StoneX Group's 13F filing for Q2 2023, filed 14 Aug 2023.